His primary scientific interests are in Surgery, Internal medicine, Ovarian cancer, Oncology and Chemotherapy. In Surgery, Ignace Vergote works on issues like Placebo, which are connected to Maintenance therapy and Phases of clinical research. In his work, Adjuvant is strongly intertwined with Gastroenterology, which is a subfield of Internal medicine.
The study incorporates disciplines such as Survival analysis, Cancer research and Serous fluid in addition to Ovarian cancer. His Oncology research integrates issues from Ovarian carcinoma, Pathology, Breast cancer and Anastrozole. In general Chemotherapy, his work in Performance status and Doxorubicin is often linked to In patient linking many areas of study.
Internal medicine, Oncology, Ovarian cancer, Surgery and Chemotherapy are his primary areas of study. His work on Cancer, Breast cancer and Carboplatin as part of general Internal medicine study is frequently linked to In patient, bridging the gap between disciplines. His Carboplatin study frequently draws connections between related disciplines such as Regimen.
His research in Oncology tackles topics such as Stage which are related to areas like Cervical cancer. His Ovarian cancer research incorporates themes from Cancer research, Serous fluid and Bioinformatics. His work on Surgery is being expanded to include thematically relevant topics such as Clinical trial.
The scientist’s investigation covers issues in Internal medicine, Oncology, Ovarian cancer, Chemotherapy and Cancer research. His Internal medicine study frequently links to related topics such as Gastroenterology. The concepts of his Oncology study are interwoven with issues in Carboplatin, Bevacizumab and Stage.
His research in Stage focuses on subjects like Cervical cancer, which are connected to Surgery and Lymph node. His research investigates the connection between Ovarian cancer and topics such as Quality of life that intersect with problems in Concomitant. His Chemotherapy research is multidisciplinary, incorporating elements of Ovarian carcinoma, Tolerability and Cohort.
Ignace Vergote focuses on Internal medicine, Ovarian cancer, Chemotherapy, Oncology and Cancer research. His Ovarian cancer research is multidisciplinary, incorporating perspectives in Maintenance therapy, Immune system and Disease. His research in Chemotherapy intersects with topics in Ovarian carcinoma, Debulking, Binimetinib and Fallopian tube.
His research integrates issues of Cancer, Tolerability, Recurrent Ovarian Cancer and Antibody-drug conjugate in his study of Oncology. His Cancer research study combines topics from a wide range of disciplines, such as Cancer cell, Cell and Epithelial ovarian cancer. His Randomized controlled trial study is focused on Surgery in general.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study
J Bonneterre;B Thurlimann;J Robertson;M Krzakowski.
Journal of Clinical Oncology (2000)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine;Jonathan A Ledermann;Frédéric Selle;Val Gebski.
Lancet Oncology (2017)
Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG
Jacobus Pfisterer;Marie Plante;Ignace Vergote;Andreas du Bois.
Journal of Clinical Oncology (2006)
Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma: European Organisation for Research and Treatment of Cancer–Adjuvant ChemoTherapy in Ovarian Neoplasm Trial
J. Baptist Trimbos;Ignace Vergote;Giorgio Bolis;Jan B. Vermorken.
Journal of the National Cancer Institute (2003)
Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
Stan B. Kaye;Jan Lubinski;Ursula Matulonis;Joo Ern Ang.
Journal of Clinical Oncology (2012)
International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.
J Baptist Trimbos;Mahesh Parmar;Ignace Vergote;David Guthrie.
Journal of the National Cancer Institute (2003)
Logistic Regression Model to Distinguish Between the Benign and Malignant Adnexal Mass Before Surgery: A Multicenter Study by the International Ovarian Tumor Analysis Group
Dirk Timmerman;Antonia Carla Testa;Tom Bourne;Enrico Ferrazzi.
Journal of Clinical Oncology (2005)
Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
Bradley J. Monk;Thomas J. Herzog;Stanley B. Kaye;Carolyn N. Krasner.
Journal of Clinical Oncology (2010)
Neoadjuvant Chemotherapy or Primary Debulking Surgery in Advanced Ovarian Carcinoma: A Retrospective Analysis of 285 Patients
I. Vergote;I. De Wever;W. Tjalma;M. Van Gramberen.
Gynecologic Oncology (1998)
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).
Gordon John Sampson Rustin;Ignace Vergote;Elizabeth Eisenhauer;Eric Pujade-Lauraine.
International Journal of Gynecological Cancer (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: